anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glycosylation is the most common form of post-translational modification in the brain. Aberrant glycosylation has been observed in cerebrospinal fluid and brain tissue of Alzheimer's disease (AD) cases, including dysregulation of terminal sialic acid (SA) modifications. While alterations in sialylation have been identified in AD, the localization of SA modifications on cellular or aggregate-associated glycans is largely unknown because of limited spatial resolution of commonly utilized methods. The present study aims to overcome these limitations with novel combinations of histologic techniques to characterize the sialylation landscape of O- and N-linked glycans in autopsy-confirmed AD post-mortem brain tissue. Sialylated glycans facilitate important cellular functions including cell-to-cell interaction, cell migration, cell adhesion, immune regulation, and membrane excitability. Previous studies have not investigated both N- and O-linked sialylated glycans in neurodegeneration. In this study, the location and distribution of sialylated glycans were evaluated in three brain regions (frontal cortex, hippocampus, and cerebellum) from 10 AD cases using quantitative digital pathology techniques. Notably, we found significantly greater N-sialylation of the Aβ plaque microenvironment compared with O-sialylation. Plaque-associated microglia displayed the most intense N-sialylation proximal to plaque pathology. Further analyses revealed distinct differences in the levels of N- and O-sialylation between cored and diffuse Aβ plaque morphologies. Interestingly, phosphorylated tau pathology led to a slight increase in N-sialylation and no influence of O-sialylation in these AD brains. Confirming our previous observations in mice with novel histologic approach, these findings support microglia sialylation appears to have a relationship with AD protein aggregates while providing potential targets for therapeutic strategies.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including oxaprozin, in pregnant women at about 30 weeks gestation and later. NSAIDs, including oxaprozin, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment 

Use of NSAIDs, including oxaprozin, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation.

Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit oxaprozin use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if oxaprozin treatment extends beyond 48 hours. Discontinue oxaprozin if oligohydramnios occurs and follow up according to clinical practice [ see Use in Specific Populations ( 8.1) ].
The invention belongs to the technical field of biological medicine, and particularly relates to a recombinant protein with high immunogenicity, virus-like particles, and a preparation method and application thereof. The recombinant protein is formed by sequentially connecting T1-B-T2, linker, bee venom signal peptide, linker, PEDV S protein and linker, CTB, WPRE, and the nucleotide sequence of the recombinant protein is shown as SEQ ID NO. 1. The invention is based on G II type PEDV S gene, and adds several elements capable of improving protein expression quantity and enhancing immunity effect to obtain recombinant protein TSCW; and further constructing a recombinant baculovirus expression vector BV-TSCW, and finally co-transfecting the BV-TSCW with BV-M to obtain the virus-like particle VLP-TSCW. The VLP-TCSW can induce higher antibody levels. The invention lays a foundation for optimizing, designing and researching and developing the subsequent PEDV vaccine.
All participants enrolled in the study will undergo baseline fMRI and baseline and follow-up (4-month post-baseline) assessment of stress physiology (i.e., allostatic load). Treatment as usual information will be gathered for all participants to assess observational intervention response.
The invention relates to surfactant preparations with a conditioning and opacifying action, containing (a) between 0.1 and 20 wt. % alkyl oligoglycosides and/or alkenyl oligoglycosides and (b) between 0.01 and 3 wt. % fatty acid partial glycerides, selected from the group composed of oleic acid monoglyceride, oleic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, docosanoic acid monoglyceride, docosanoic acid diglyceride, isodocosanoic acid monoglyceride and/or isodocosanoic acid diglyceride, (c) between 0.05 and 10 wt. % alkene glycol fatty acid esters, optionally (d) between 0 and 3 wt. % polymeric thickening agents, in addition to optionally (e) between 0 and 5 wt. % polyols and optionally (f) between 0 and 1 wt. % cationic polymers, with the proviso that the sum of the indicated quantities amounts to 100 wt. %, optionally by adding conventional auxiliary agents, additives and/or water. The blends exhibit an opacifying action that is stable during storage, a particularly good dermatological compatibility and despite excellent cleansing properties, an optimal conditioning action.
Diazepam 0.5 mg/kg (up to maximum 20 mg) by mouth nightly. Duration of therapy is 4 weeks.
Objectives: To evaluate the effectiveness of antihypertensive treatment maintenance with 1.5 g / day of methyldopa for controlling maternal blood pressure in pregnant women with severe pre-eclampsia and stable blood pressure. Methods: A clinical, randomized, triple-masked, placebo-controlled study will be conducted at the Instituto de Medicina Integral Prof. Fernando Figueira from March 2011 to March 2012. The study will include 200 patients with severe preeclampsia between 20 to 34 weeks of gestation, which will be randomized into two groups: placebo and methyldopa. Patients with more severe hypertensive disorders, congenital anomalies and maternal medical complications or conditions that may compromise the mother-child well-being will be excluded from the study. The primary outcomes will be: systolic, diastolic and mean maternal heart rate, need for association with another antihypertensive agent, need and reason for discontinuation of treatment, frequency of hypertensive peaks and uncontrolled hypertension. The variables relating to maternal characteristics of pregnancy, clinical and obstetric complications during pregnancy and after delivery, and adverse perinatal outcomes will be considered secondary outcomes. After inclusion of patients in the study, numbered boxes containing methyldopa or placebo will be offered to patients with appropriate explanations about oral administration. The initial dose of methyldopa is 1.5 g / day divided into three daily doses and can be reduced to 1.0 g / day or increased to 2.0 g / day depending on the clinical need of patients. On the other group, three tablets / day of placebo will be administered and this dose may be reduced or increased to two tablets to four tablets per day. Statistical analysis will be performed using the statistical program Epi-Info 3.5.1. and Minitab, version 14.2. for Windows. The analysis will be performed with the groups identified as A or B, and the secrecy will be broken only after obtaining the results and preparing the tables or by resolution of the Committee for External Monitoring. Categorical variables will be compared in contingency tables, using chi-square and Fisher exact test, when appropriate. Risk ratio (RR) and its 95% confidence interval will be calculated as a measure of relative risk. Regarding the quantitative variables, if they have normal distribution, comparison between groups will be performed using the Student t test for unpaired samples. If it is found that the distribution is not normal, the nonparametric Mann-Whitney test will be used.
OBJECTIVES: Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 is a clinical and research standard for evaluating malignant tumors and lymph node metastasis. However, quantitative analysis of nodal status is limited to measurement of short axis diameter (SAD), and metastatic lymph nodes below 10 mm in SAD are often not detected. The purpose of this study was to evaluate the value of multifrequency magnetic resonance elastography (MRE) when added to RECIST 1.1 for detection of lymph node metastasis.
MATERIALS AND METHODS: Twenty-five benign and 82 metastatic lymph nodes were prospectively examined by multifrequency MRE at 1.5 T using tomoelastography postprocessing at 30, 40, 50, and 60 Hz (total scan time of 4 minutes). Shear wave speed as a surrogate of soft tissue stiffness was provided in m/s. Positron emission tomography-computed tomography was used as reference standard for identification of abdominal lymph node metastasis from histologically confirmed primary tumors. The diagnostic performance of MRE was compared with that of SAD according to RECIST 1.1 and evaluated by receiver operating characteristic curve analysis using generalized linear mixed models and binary logistic mixed models. Sensitivity, specificity, and predictive values were calculated for different cutoffs.
RESULTS: Metastatic lymph nodes (1.90 ± 0.57 m/s) were stiffer than benign lymph nodes (0.98 ± 0.20 m/s, P < 0.001). An area under the curve of 0.95 for a cutoff of 1.32 m/s was calculated. Using a conservative approach with 1.0 specificity, we found sensitivity (SAD/MRE/MRE + SAD, 0.56/0.84/0.88), negative predictive values (0.41/0.66/0.71), and overall accuracy (0.66/0.88/0.91) to be improved using MRE and even higher for combined MRE and SAD.
CONCLUSIONS: Multifrequency MRE improves metastatic abdominal lymph node detection by 25% based on higher tissue stiffness-even for lymph nodes with an SAD ≤10 mm. Stiffness information is quick to obtain and would be a promising supplement to RECIST.
Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
Patients will be assigned to acupressure and control groups according to the randomization list prepared earlier by the investigators.

First of all, all patients will be informed about the procedure and their informed consent will be obtained. Patients in the acupuncture and control groups will be evaluated with the patient evaluation form, VAS and State Anxiety Inventory 15 minutes before venipuncture. Demographic information of each patient will be recorded by the investigator. The pain level, satisfaction level and anxiety levels of the patients will be recorded before the venipuncture procedure. The following applications will be made 10 minutes before the patients in the acupressure group. Hands are washed before applying acupressure. Before applying acupressure, the patient is allowed to sit in a comfortable position on the sofa in the single venipuncture room. Before starting the acupressure application, the arm is rubbed from fingertips to the elbow to relax, and press the acupressure points (Large Intestine Meridian 4th Point \[LI 4\], Large Intestine Meridian 11th Point \[LI 11\], and Heart Meridian 7th Point \[HT 7\]). application is carried out. 2 minutes to each acupressure point. pressure (3 to 5 kg of pressure) is applied. Only one acupressure session is performed for each patient, and each acupressure session will last 10 minutes (WHO, 2008). Acupressure application is applied before venipuncture. Venipuncturen is performed immediately after the acupressure session. While performing the acupuncture procedure and venipuncture, other patients participating in the study will not see each other during the application phase. Venipuncture will be applied to all patients by the same nurse in the same room. Venipuncture will be performed on the left arm of all patients with a vacuum tube using a 0.8 \* 38 mm (21G x 1½, green) needle tip. Immediately after the venipuncture, the pain and satisfaction assessment of the patients during the procedure will be made with the VAS (Pain and Satisfaction) and State Anxiety Inventory. The pain level, satisfaction level and anxiety levels of the patients will be recorded before the venipuncture procedure. All of the measurement results were obtained by another researcher blinded to group allocation. All procedures will take approximately 20-25 minutes for each participant.
Recombinant human proteoglycan 4 (rhPRG4) is a macromolecular mucin-like glycoprotein that is classically studied as a lubricant within eyes and joints. Given that endogenously produced PRG4 is present within atherosclerotic lesions and genetic PRG4 deficiency increases atherosclerosis susceptibility in mice, in the current study we investigated the anti-atherogenic potential of chronic rhPRG4 treatment. Female low-density lipoprotein receptor knockout mice were fed an atherogenic Western-type diet for 6 weeks and injected three times per week intraperitoneally with 0.5 mg rhPRG4 or PBS as control. Treatment with rhPRG4 was associated with a small decrease in plasma-free cholesterol levels, without a change in cholesteryl ester levels. A marked increase in the number of peritoneal foam cells was detected in response to the peritoneal rhPRG4 administration, which could be attributed to elevated peritoneal leukocyte MSR1 expression levels. However, rhPRG4-treated mice exhibited significantly smaller aortic root lesions of 278 ± 21 × 103 μm2 compared with 339 ± 15 × 103 μm2 in the aortic root of control mice. The overall decreased atherosclerosis susceptibility coincided with a shift in the monocyte and macrophage polarization states towards the patrolling and anti-inflammatory M2-like phenotypes, respectively. Furthermore, rhPRG4 treatment significantly reduced macrophage gene expression levels as well as plasma protein levels of the pro-inflammatory/pro-atherogenic cytokine TNF-alpha. In conclusion, we have shown that peritoneal administration and subsequent systemic exposure to rhPRG4 beneficially impacts the inflammatory state and reduces atherosclerosis susceptibility in mice. Our findings highlight that PRG4 is not only a lubricant but also acts as an anti-inflammatory agent. KEY POINTS: Endogenously produced proteoglycan 4 is found in atherosclerotic lesions and its genetic deficiency in mice is associated with enhanced atherosclerosis susceptibility. In this study we investigated the anti-atherogenic potential of chronic treatment with recombinant human PRG4 in hypercholesterolaemic female low-density lipoprotein receptor knockout mice. We show that recombinant human PRG4 stimulates macrophage foam cell formation, but also dampens the pro-inflammatory state of monocyte/macrophages, eventually leading to a significant reduction in plasma TNF-alpha levels and a lowered atherosclerosis susceptibility. Our findings highlight that peritoneal recombinant human PRG4 treatment can execute effects both locally and systemically and suggest that it will be of interest to study whether rhPRG4 treatment is also able to inhibit the progression and/or induce regression of previously established atherosclerotic lesions.
Belonging to the field of medical technologies, the present invention discloses application of aloe-emodin in preparation of drugs reducing blood lipid and liver lipid. Specifically, blood lipid refers to total cholesterol and low density lipoprotein in serum, and liver lipid refers to total cholesterol in liver. Toxicity tests show that aloe-emodin has no obvious toxic and side effect. Pharmacodynamic tests of aloe-emodin show that aloe-emodin can significantly reduce the total cholesterol and low density lipoprotein in hyperlipidemia animal model serum, and has obvious blood lipid reducing effect. At the same time, aloe-emodin can also significantly reduce the total cholesterol content of a hyperlipidemia animal model liver, and has obvious liver lipid reducing effect. Therefore, the invention puts forward the application of aloe-emodin in reduction of blood lipid and liver lipid, aloe-emodin has the characteristics of significant lipid reducing effect, low toxicity, no irritation, low price, and convenient production, transportation, storage and taking, and can have broad application prospects as a blood lipid and liver lipid reducing drug.
Strong CYP3A4 Inhibitors

Coadministration of INREBIC with a strong CYP3A4 inhibitor increases fedratinib exposure [see Clinical Pharmacology (12.3)]. Increased exposure may increase the risk of adverse reactions. Consider alternative therapies that do not strongly inhibit CYP3A4 activity. Alternatively, reduce the dose of INREBIC when administering with a strong CYP3A4 inhibitor [see Dosage and Administration (2.4)].

Strong and Moderate CYP3A4 Inducers

Coadministration of INREBIC with a strong or moderate CYP3A4 inducer can decrease fedratinib exposure [see Clinical Pharmacology (12.3)]. Decreased exposure may reduce the effectiveness of INREBIC. Avoid INREBIC with strong and moderate CYP3A4 inducers.

Dual CYP3A4 and CYP2C19 Inhibitors

Coadministration of INREBIC with a dual CYP3A4 and CYP2C19 inhibitor increases fedratinib exposure [see Clinical Pharmacology (12.3)]. Increased exposure may increase the risk of adverse reactions. Due to potential increase of exposure, patients taking concomitant dual CYP3A4 and CYP2C19 inhibitors require more intensive safety monitoring and, if necessary, dose modifications of INREBIC based on adverse reactions [see Dosage and Administration (2.6)].
PURPOSE:To prepare the titled emulsion cosmetic having high gel stability, preservable for a long period, and giving refreshing feeling to the skin, by adding an aqueous solution of a water-soluble polymer to liquid lipophilic surface active agent at normal temperature, and dispersing the resultant gel in an oily component. CONSTITUTION:An aqueous solution of a water-soluble polymer is added to a lipophilic surface active agent which is liquid at normal temperature, e.g.  glycerin monooleate, under stirring to obtain a gel. The gel is dispersed in an  oily component, and if necessary added with water to obtain the objective emulsion cosmetic. The water-soluble polymer is e.g. sodium arginate, sodium  pectinate, sodium carboxy-methylcellulose, carboxyvinyl polymer, etc. or their mixture. The amount of the lipophilic surface active agent is 0.5-8wt% of the  whole composition, and the amount of the water-soluble polymer is 1-10 times  weight of the lipophilic surface active agent in terms of 0.1-5% aqueous solution.
Absorption

Oral absorption of acitretin is optimal when given with food. For this reason, acitretin was given with food in all of the following trials. After administration of a single 50-mg oral dose of acitretin to 18 healthy subjects, maximum plasma concentrations ranged from 196 to 728 ng per mL (mean: 416 ng per mL) and were achieved in 2 to 5 hours (mean: 2.7 hours). The oral absorption of acitretin is linear and proportional with increasing doses from 25 to 100 mg. Approximately 72% (range: 47% to 109%) of the administered dose was absorbed after a single 50-mg dose of acitretin was given to 12 healthy subjects.

Distribution

Acitretin is more than 99.9% bound to plasma proteins, primarily albumin.

Metabolism (See Pharmacokinetic Drug Interactions, Ethanol.)

Following oral absorption, acitretin undergoes extensive metabolism and interconversion by simple isomerization to its 13-cis form (cis-acitretin). The formation of cis-acitretin relative to parent compound is not altered by dose or fed/fast conditions of oral administration of acitretin. Both parent compound and isomer are further metabolized into chain-shortened breakdown products and conjugates, which are excreted. Following multiple-dose administration of acitretin, steady-state concentrations of acitretin and cis-acitretin in plasma are achieved within approximately 3 weeks.

Elimination

The chain-shortened metabolites and conjugates of acitretin and cis-acitretin are ultimately excreted in the feces (34% to 54%) and urine (16% to 53%). The terminal elimination half-life of acitretin following multiple-dose administration is 49 hours (range: 33 to 96 hours), and that of cis-acitretin under the same conditions is 63 hours (range: 28 to 157 hours). The accumulation ratio of the parent compound is 1.2; that of cis-acitretin is 6.6.
PROBLEM TO BE SOLVED: To obtain the subject new gene coding a new isoform of cell-stroma desmosome protein paxillin, and useful for developing medicines for cancer therapies such as diagnosing cancer malignancy advancement and restraining metastasis or cancer cell infiltration. SOLUTION: This gene is a new isoform (paxillin β) gene of cell-stroma desmosome protein paxillin, coding an amino acid sequence virtually shown by formula I, or another new isoform (paxillin γ) of the paxillin, coding an amino acid sequence virtually shown by formula II. This gene is hopeful of medical applications, e.g. the development of medicines for cancer therapies such as diagnosing cancer malignancy advancement and restraining metastasis or cancer cell infiltration. This gene is obtained by the following process: a mRNA is isolated from human mononuclear blast cells V937, and, from the mRNA, a cDNA is synthesized using a reverse transcriptase, and then subjected to PCR amplification using e.g. a partial sequence of human paxillin a as primer.
Children with specific phobias may experience academic, social, and personal distress, as well as interference in day-to-day activities. One-Session Treatment has been found a rapid and effective treatment for adults with phobic disorders. However, its utility in the treatment of childhood phobia has not been examined.

Participants are randomly assigned to 1 of 3 groups: a one-session treatment group, an education/support group, and a waitlist control group. The one-session treatment group is directly exposed to a phobia object or situation during a 3-hour treatment session. In the education/support group, children are given information about fear and phobias and are taught how to deal with them through workbook activities. Children who participate in the one-session treatment group or the education/support group are assessed 1 week post-treatment and again after 6 months. Participants with improved symptoms have a 1-year follow-up. Participants with phobias that persist at 6 months are encouraged to participate in alternative treatment. Waitlist control participants are assessed pre-treatment and 1 month post-treatment. Those who continue to have phobias at the 1-month assessment are randomly assigned to 1 of the 2 active treatments.
<P>PROBLEM TO BE SOLVED: To provide a new gene expression promoting agent for skin beautifying use, effective for promoting the expression of a skin-beautifying gene such as aquaporin 3, aquaporin 5, serine palmitoyl transferase enzyme and hyaluronic acid synthase.  <P>SOLUTION: The gene expression promoting agent for skin beautifying use contains an extract of a plant of the genus Fragaria L., family Rosaceae as an active component. The extract preferably contains tiliroside. The part of the plant of the genus Fragaria L., family Rosaceae to be used in the agent is preferably seed. The invention is widely usable for foods, drinks, pharmaceuticals, skin care preparations, etc.  <P>COPYRIGHT: (C)2010,JPO&INPIT